TrialBridgeNCT06076538
PET/MR for Characterization of Renal Masses (RMs)
Recruiting · Not specified · University of Texas Southwestern Medical Center · registry updated 2026-08-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatment. Many cancerous kidney tumors are indolent and can be followed safely with imaging (i.e., particularly tumors \<2 cm and in patients with limited life expectancy), while some tumors are both malignant and aggressive, with a higher potential to spread outside the kidney and require treatment. The purpose of this observational study is to assess the ability of Fludeoxyglucose (18F) (FDG) PET/MR to distinguish different types of kidney tumors. The investigators hypothesize that PET/MR will better show differences between aggressive and both indolent and benign kidney masses compared to the currently used radiologic scans. Participants will be selected from those who have been scheduled to receive a contrast-enhanced MRI for their regular care due to a suspicious kidney mass. Participants will have their MRI on a hybrid PET/MR scanner capable of obtaining both MRI and PET images....
Inclusion
- Patients with known solid (\>25% total volume enhances) renal mass
- Renal mass size measuring \>2 to ≤7 cm
- Age \>18 years
- Ability to understand and the willingness to sign a written informed consent.
Exclusion
- Prior percutaneous biopsy of the renal mass
- Prior treatment of the renal mass
- Prior hemorrhage in the renal mass
- Contraindication to MRI or PET
- Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \[classic angiomyolipoma\] or enhancing less than 25% of its volume \[considered a cystic renal mass\])
- Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);